The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.

All material subject to strictly enforced copyright laws. © 2021 Euromoney, a part of the Euromoney Institutional Investor PLC.
Capital Markets

Insurance securitization: Finding a way to cope with mortality

AXA’s proposed extreme mortality cat bond will set the tone for the insurance securitization sector this year.

Having applied securitization to its vehicle insurance book last year via the innovative FCC Sparc deal, AXA now plans to offload mortality risk to the capital markets via a synthetic securitization to be arranged by Ixis CIB, Lehman Brothers and Swiss Re Capital Markets. The two types of risk are very different: the FCC Sparc deal dealt with high-frequency, low-severity claims whereas the mortality deal looks to address lower-frequency, higher-severity cover.

Mortality risk has been securitized before, principally via Swiss Re’s Vita Capital deals. The drivers for an insurance company to offload mortality risk include regulatory considerations and diversification of funding sources, but the rising cost of reinsurance has also weighed in the technique’s favour. Traditionally, reinsurers have been willing to price whatever risks are offered to them but they may become increasingly unwilling to take on mortality and life insurance risks. “There is limited capacity for peak mortality reinsurance, and securitization offers an alternative,” says Jonathan Spry, associate director at Standard & Poor’s and head of the agency’s insurance team.

Hard to quantify

Mortality risk differs from other types of insurance risk in that it involves a single risk: death. Other insurance securitizations, such as the value-in-force (VIF) deals (for example, Box Hill Life Finance) involve multiple risks such as longevity, mortality and price, whereas with mortality there is really only one variable.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.


Unlimited access to and

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually


Unlimited access to and, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors


Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree